1: Pozzi C, Lopresti L, Santucci M, Costi MP, Mangani S. Evidence of
Destabilization of the Human Thymidylate Synthase (hTS) Dimeric Structure Induced
by the Interface Mutation Q62R. Biomolecules. 2019 Apr 3;9(4). pii: E134. doi:
10.3390/biom9040134. PubMed PMID: 30987202; PubMed Central PMCID: PMC6523895.
2: Pozzi C, Ferrari S, Luciani R, Costi MP, Mangani S. Structural and Functional
Characterization of the Human Thymidylate Synthase (hTS) Interface Variant R175C,
New Perspectives for the Development of hTS Inhibitors. Molecules. 2019 Apr
7;24(7). pii: E1362. doi: 10.3390/molecules24071362. PubMed PMID: 30959951;
PubMed Central PMCID: PMC6479699.
3: Vanossi D, Caselli M, Pavesi G, Borsari C, Linciano P, Costi MP, Ponterini G.
Excited-state intramolecular proton transfer in a bioactive flavonoid provides
fluorescence observables for recognizing its engagement with target proteins.
Photochem Photobiol Sci. 2019 Mar 22. doi: 10.1039/c9pp00026g. [Epub ahead of
print] PubMed PMID: 30900698.
4: Saxena P, Severi L, Santucci M, Taddia L, Ferrari S, Luciani R, Marverti G,
Marraccini C, Tondi D, Mor M, Scalvini L, Vitiello S, Losi L, Fonda S, Pacifico
S, Guerrini R, D'Arca D, Ponterini G, Costi MP. Conformational Propensity and
Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate
Synthase and Ovarian Cancer Cell Growth. J Med Chem. 2018 Aug
23;61(16):7374-7380. doi: 10.1021/acs.jmedchem.7b01699. Epub 2018 Aug 13. PubMed
PMID: 30035541.
5: Severi L, Losi L, Fonda S, Taddia L, Gozzi G, Marverti G, Magni F, Chinello C,
Stella M, Sheouli J, Braicu EI, Genovese F, Lauriola A, Marraccini C, Gualandi A,
D'Arca D, Ferrari S, Costi MP. Proteomic and Bioinformatic Studies for the
Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian
Cancer. Front Pharmacol. 2018 May 8;9:454. doi: 10.3389/fphar.2018.00454.
eCollection 2018. PubMed PMID: 29867465; PubMed Central PMCID: PMC5952181.
6: Rondanin R, Lettini G, Oliva P, Baruchello R, Costantini C, Trapella C, Simoni
D, Bernardi T, Sisinni L, Pietrafesa M, Ponterini G, Costi MP, Vignudelli T,
Luciani R, Matassa DS, Esposito F, Landriscina M. New TRAP1 and Hsp90 chaperone
inhibitors with cationic components: Preliminary studies on mitochondrial
targeting. Bioorg Med Chem Lett. 2018 Jul 15;28(13):2289-2293. doi:
10.1016/j.bmcl.2018.05.031. Epub 2018 May 15. PubMed PMID: 29807796.
7: Ferrari S, Severi L, Pozzi C, Quotadamo A, Ponterini G, Losi L, Marverti G,
Costi MP. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.
Vitam Horm. 2018;107:473-513. doi: 10.1016/bs.vh.2017.12.002. Epub 2018 Feb 12.
Review. PubMed PMID: 29544641.
8: Lettini G, Maddalena F, Sisinni L, Condelli V, Matassa DS, Costi MP, Simoni D,
Esposito F, Landriscina M. TRAP1: a viable therapeutic target for future cancer
treatments? Expert Opin Ther Targets. 2017 Aug;21(8):805-815. doi:
10.1080/14728222.2017.1349755. Epub 2017 Jul 18. Review. PubMed PMID: 28664757.
9: Sacchetti F, D'Arca D, Genovese F, Pacifico S, Maretti E, Hanuskova M,
Iannuccelli V, Costi MP, Leo E. Conveying a newly designed hydrophilic anti-human
thymidylate synthase peptide to cisplatin resistant cancer cells: are
pH-sensitive liposomes more effective than conventional ones? Drug Dev Ind Pharm.
2017 Mar;43(3):465-473. doi: 10.1080/03639045.2016.1262870. Epub 2016 Dec 26.
PubMed PMID: 27885848.
10: Siragusa L, Luciani R, Borsari C, Ferrari S, Costi MP, Cruciani G, Spyrakis
F. Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The
Thymidylate Synthase Case. ChemMedChem. 2016 Aug 5;11(15):1653-66. doi:
10.1002/cmdc.201600121. Epub 2016 Jul 12. PubMed PMID: 27404817.
11: Ponterini G, Martello A, Pavesi G, Lauriola A, Luciani R, Santucci M, Pelà M,
Gozzi G, Pacifico S, Guerrini R, Marverti G, Costi MP, D'Arca D. Intracellular
quantitative detection of human thymidylate synthase engagement with an
unconventional inhibitor using tetracysteine-diarsenical-probe technology. Sci
Rep. 2016 Jun 2;6:27198. doi: 10.1038/srep27198. PubMed PMID: 27250901; PubMed
Central PMCID: PMC4890114.
12: Taddia L, D'Arca D, Ferrari S, Marraccini C, Severi L, Ponterini G, Assaraf
YG, Marverti G, Costi MP. Inside the biochemical pathways of thymidylate synthase
perturbed by anticancer drugs: Novel strategies to overcome cancer
chemoresistance. Drug Resist Updat. 2015 Nov;23:20-54. doi:
10.1016/j.drup.2015.10.003. Epub 2015 Oct 31. Review. PubMed PMID: 26690339.
13: Sacchetti F, Marraccini C, D'Arca D, Pelà M, Pinetti D, Maretti E, Hanuskova
M, Iannuccelli V, Costi MP, Leo E. Enhanced anti-hyperproliferative activity of
human thymidylate synthase inhibitor peptide by solid lipid nanoparticle
delivery. Colloids Surf B Biointerfaces. 2015 Dec 1;136:346-54. doi:
10.1016/j.colsurfb.2015.09.040. Epub 2015 Sep 25. PubMed PMID: 26433347.
14: Salo-Ahen OM, Tochowicz A, Pozzi C, Cardinale D, Ferrari S, Boum Y, Mangani
S, Stroud RM, Saxena P, Myllykallio H, Costi MP, Ponterini G, Wade RC. Hotspots
in an obligate homodimeric anticancer target. Structural and functional effects
of interfacial mutations in human thymidylate synthase. J Med Chem. 2015 Apr
23;58(8):3572-81. doi: 10.1021/acs.jmedchem.5b00137. Epub 2015 Apr 1. PubMed
PMID: 25798950; PubMed Central PMCID: PMC4634673.
15: Santucci M, Vignudelli T, Ferrari S, Mor M, Scalvini L, Bolognesi ML, Uliassi
E, Costi MP. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as
Targets for Regenerative Medicine and Cancer Treatment. J Med Chem. 2015 Jun
25;58(12):4857-73. doi: 10.1021/jm501615v. Epub 2015 Mar 11. Review. PubMed PMID:
25719868.
16: Tochowicz A, Santucci M, Saxena P, Guaitoli G, Trande M, Finer-Moore J,
Stroud RM, Costi MP. Alanine mutants of the interface residues of human
thymidylate synthase decode key features of the binding mode of allosteric
anticancer peptides. J Med Chem. 2015 Jan 22;58(2):1012-8. doi:
10.1021/jm5011176. Epub 2014 Dec 29. PubMed PMID: 25427005.